Environment – Planet First
| Theme | Description | Target | FY 2025 Progress |
|---|---|---|---|
| Reducing carbon emissions | Adopting renewable power | 100% renewable power by 2030 | 68% of our power was through renewable sources |
| Progressing towards carbon neutrality | Carbon neutrality in our direct operations (Scope 1 & Scope 2) by 2030 | 60% Carbon neutrality Achieved so far | |
| Reducing carbon emissions in the supply chain | 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030 | 5% decrease in reported Scope 3 emissions against FY2021 | |
| Water Positivity | To be a water positive organisation | Be water positive by 2025 | Continued to be a water positive company post achieving the target in FY2023 |
| Access | Serving maximum patients with care | Serve 1.5 billion patients by 2030 | ~756 million patients served |
| Affordability | Introducing first-to-market solutions | *40% of our new launches to be first-to-market in our #priority markets by 2030 | 29% |
| Innovation | Improving treatment standards regularly | 3 innovative solutions every year from 2027 to improve the standard of treatment | Toripalimab and Evenity launched in India |
| Equitable Growth | |||
| Theme | Description | Target | FY 2025 Progress |
| Diversity, equity, and inclusion | Enhancing women leadership | At least 35% women in senior Leadership by 2030 | 20.4% |
| Promoting gender parity | Gender parity by 2035 | 21.8% | |
| Equal opportunity for the persons with disabilities (PhDs) | Include at least 3% persons with disabilities (PwD) in our workforce by 2030 | 0.43% | |
Governance – Trusted Relationships
| Theme | Description | Target | FY 2025 Progress |
|---|---|---|---|
| Corporate Governance | Committed to upholding the highest standards of compliance and ethics | Meet the highest standards on compliance and ethics backed by Robust corporate governance | Zero material deviations recorded During the year |
| ESG Disclosures | Transparency and communication around our ESG performance | Enhance disclosure on our ESG progress to reach the top Quartile by 2025 | Enhanced ESG disclosures with wider coverage of KPIs, increased reporting frameworks, and double materiality assessment |
| Strategic Suppliers | Embedding ESG principles across our supply chain | 100% strategic suppliers to be compliant with our chosen ESG framework by 2030 | 73% of strategic suppliers (India Spend) assessed |
Our ESG (Environment, Social & Governance) Goals:
Being committed to environmental stewardship
- Reducing carbon emissions
- 100% renewable power by 2030
- Carbon neutrality in our direct operations (Scope 1 & Scope 2) by 2030
- 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030
- Reducing carbon emissions
- 100% renewable power by 2030
- Carbon neutrality in our direct operations (Scope 1 & Scope 2) by 2030
- 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030
Making our products accessible and affordable for patients
- Access
- Serve 1.5 billion patients by 2030.
- Affordability
- 25% of our new-launches to be first-to-market by 2027.
- Innovation
- 3 innovative solutions to improve the standard of treatment every year from 2027.
Contributing to a fairer and more socially inclusive world
- Equity, diversity, and inclusion
- At least 35% women in senior leadership by 2030
- Gender parity by 2035
- Include at least 3% persons with disabilities (PwD) in our workforce by 2030.
- 100% living wages for our on-premises extended workforce by 2025.
Enhancing trust with our stakeholders
- Highest standards of compliance
- Meet the highest standards on compliance and ethics backed by robust corporate governance ESG disclosures.
- ESG Disclosures: Progressively enhance disclosure on our ESG progress to reach top quartile by 2025.
- Strategic Suppliers: 100% strategic suppliers to be compliant with our ESG framework by 2030.
- Affordability
- Innovation
What we achieved in the past year:
3.8
Bn total revenue (17% growth)
165
New products launched
111
DMFs filed, (1,630+ Cumulative DMFs)
249
Dossiers, including 10 ANDAs filed
76
Filings in the US pending for approval
20.4%
Women in leadership
96%
Employees trained for skill upgradation
0.14 to 0.07
*LTIFR reduced from
126
Differently abled employees
700,000+
Lives impacted through CSR
783
Million KL of water saved through agri-water saving techniques
66,723
MTCO2e of direct emissions reduction
11%
Reduction in water intensity per rupee of turnover with respect to FY2024
60%
Carbon neutrality achieved
75,761
KL of harvested rainwater used
54%
Water reused/recycled
Estamos aquí para ayudarte, si tienes algún requisito específico para tu país.
Our Community Initiatives
Education
- Enhance the quality of education and provide equal learning opportunities to the children from the marginalised communities through:
- Kallam Anji Reddy Vidyalaya and Junior Vocational College
- School Improvement Programme (SIP)
- Sashakt scholarship for girls
Livelihood
- Provide skills to youth for enhancing their employability and to enhance livelihoods by extending support to small and marginal farmers through:
- Placement-linked skilling programme for youths and Persons with Disability
- Healthcare Skilling in the non–medical healthcare sector
- Agriculture programme focusing on capacity and income enhancement of small and marginalised farmers.
Health
- Making healthcare accessible and affordable, and reliable for the communities through:
- Rural healthcare services at the doorstep through the Community Health Intervention Program
- Tele-counselling support for mental health through the Roshni Helpline
- Include at least 3% persons with disabilities (PwD) in our workforce by 2030.
- Improving primary healthcare services to improve the quality of primary care services in the selected Primary Healthcare Centres
To know more about our Sustainability/ESG initiatives and programmes read our full sustainability report here.
Descargo de responsabilidad
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.